At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,100 enrolled
Drug / intervention
BEACOPPescalated (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone) +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
HD17 for Intermediate Stages - Treatment Optimization Trial in the First-Line Treatment of Intermediate Stage Hodgkin Lymphoma
In Brief
A Phase 3 clinical trial evaluating BEACOPPescalated (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone), ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine), and 2 other interventions for Hodgkin Lymphoma. Completed, enrolled 1,100 participants across 1 site.
Detailed Summary
This study is designed to test the non-inferiority of the experimental arm compared to the standard arm in terms of progression free survival (PFS).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHodgkin Lymphoma
CountriesGermany
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2011
Enrollment StartJan 2012
Primary CompletionMar 2020
Study CompletionMar 2020
TodayJul 2026
First PostedMay 19, 2011
Enrollment StartJan 13, 2012
Primary CompletionMar 21, 2020
Study CompletionMar 23, 2020
TodayJul 2, 2026
Enrollment to primary: 8.2 yearsPosted 15.1 years ago
Interventions
BEACOPPescalated (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone)drug
ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine)drug
30Gy IF-RT (Involved-Field Radiotherapy)radiation
30Gy IN-RT (Involved-Node Radiotherapy)radiation